TY - JOUR AU - Wang, Changjun AU - Lin, Yan AU - Zhou, Yidong AU - Mao, Feng AU - Zhu, Hanjiang AU - Guan, Jinghong AU - Zhang, Xiaohui AU - Shen, Songjie AU - Huang, Xin AU - Chen, Chang AU - Yao, Ru AU - Zhao, Jialin AU - Sun, Qiang PY - 2020 DA - 2020/07/13 TI - Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial JO - BMC Cancer SP - 653 VL - 20 IS - 1 AB - HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a novel irreversible epidermal growth factor receptor/HER2 dual tyrosine kinase inhibitor. However, there is scarcity of data on the effectiveness and safety of pyrotinib combined with trastuzumab and AI as first-line treatment in a metastatic setting. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07143-2 DO - 10.1186/s12885-020-07143-2 ID - Wang2020 ER -